Status:

COMPLETED

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure

Lead Sponsor:

Jakob Stensballe, MD, PhD

Collaborating Sponsors:

Innovation Fund Denmark

Independent Research Fund Denmark

Conditions:

Septic Shock

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

The purpose of this trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in up to a total of 380 patients with sep...

Detailed Description

Patients with the most severe type of sepsis, those with septic shock have a mortality rate between 30% to 45% due to multiple organ failure. The poor outcome of shocked patients, and especially those...

Eligibility Criteria

Inclusion

  • All the following criteria must be fulfilled:
  • Adult intensive care patients (age ≥ 18 years)
  • Septic shock defined according to the Sepsis-3 criteria:
  • suspected or documented infection
  • persisting hypotension requiring vasopressors to maintain a mean arterial blood pressure of 65 mmHg or above
  • Lactate level of 2 mmol/L or above despite fluid therapy within the last 3 hours at screening
  • Soluble thrombomodulin (sTM) above 10 ng/mL

Exclusion

  • Patients who fulfil any of the following criteria will be excluded:
  • Withdrawal from active therapy
  • Pregnancy
  • Known hypersensitivity to iloprost.
  • Life-threatening bleeding as defined by the treating physician
  • Known severe heart failure (New York Heart Association (NYHA) class IV)
  • Suspected acute coronary syndrome
  • Previously included in this trial
  • Septic shock for more than 12 hours at the time of screening
  • Informed consent cannot be obtained
  • Included in other clinical trials with prostacyclin within 90 days

Key Trial Info

Start Date :

October 30 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 28 2022

Estimated Enrollment :

279 Patients enrolled

Trial Details

Trial ID

NCT04123444

Start Date

October 30 2019

End Date

June 28 2022

Last Update

May 7 2024

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital

Copenhagen, Denmark

2

Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet

Copenhagen, Denmark

3

Dept. of Intensive Care, Copenhagen University Hospital Herlev

Herlev, Denmark

4

Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital

Hillerød, Denmark